Date: Sep 24, 2024 06:00 PM - 08:30 PM
Fee
$0.00
CE Hours
2.50
CE Units
0.250
Registration closes on Nov 08, 2024 10:00 PM
Activity Type
- Knowledge
Target Audience(s)
- Pharmacist
Accreditation(s)
Accreditation Statement: Howard University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Objectives
- Identify the recommended populations for PrEP usage as outlined by current healthcare guidelines within the context of HIV prevention.
- List at least three barriers to PrEP adherence
- Explain four strategies to enhance PrEP adherence among users
Speaker(s)/Author(s)
|
Derrick Darbouze, PharmD. |
Activity Number
0010-9999-24-059-L02-P
Date:
09/24/24
Time:
06:00 PM - 06:45 PM
CE Hours
0.75
Objectives
- Describe the mechanism of action, indications for use, and efficacy and safety of injectable antiretrovirals, e.g., cabotegravir, rilpivirine, lenacapavir and ibalizumab.
- Outline updated data for long acting injectable (LAI) cabotegravir/rilpivirine for treatment.
- Explain monitoring strategies for oral vs. injectable HIV pre-exposure prophylaxis (PrEP).
Speaker(s)/Author(s)
|
John Hogan, MD |
Activity Number
0010-9999-24-060-L02-P
Date:
09/24/24
Time:
06:45 PM - 07:30 PM
CE Hours
0.75
Objectives
- Explain pharmacovigilance and its relationship with medication safety in the care of populations including persons living with HIV infection.
- Identify 3 external and internal sources of pharmacovigilance data available to practicing pharmacy professionals for long acting injectable antiretrovirals (ARVs).
- Describe the FDA Adverse Event Reporting System (FAERS II) and how pharmacy professionals and other health professionals support and use it to advance safe use on long acting injectable ARVs, e.g., cabotegravir and rilpivirine.
Speaker(s)/Author(s)
|
Dr. Christopher Keeys, Pharm.D.,BCPS, Pharm.D., BCPS
|
Activity Number
0010-9999-24-061-L05-P
Date:
09/24/24
Time:
07:30 PM - 08:30 PM
CE Hours
1.00